Petros Pharmaceuticals, Inc. Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic
Petros Pharmaceuticals, Inc. (PTPI) reported Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic of $6.41 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Income Statement › Other Income
us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic · last filed 2026-08-13
- Petros Pharmaceuticals, Inc. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2025-12-31 was $0.00.
- Petros Pharmaceuticals, Inc. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2025-09-30 was $0.00.
- Petros Pharmaceuticals, Inc. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2025-06-30 was $7.47M.
- Petros Pharmaceuticals, Inc. net income (loss) from discontinued operations available to common shareholders, basic for the quarter ending 2025-03-31 was -$1.06M.
- Petros Pharmaceuticals, Inc. net income (loss) from discontinued operations available to common shareholders, basic for fiscal 2025 was $6.41M.
- Petros Pharmaceuticals, Inc. net income (loss) from discontinued operations available to common shareholders, basic for fiscal 2024 was -$13.61M.
| Period end | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 3 month | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 6 month | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 9 month | Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $0.00 derived: sum of 2 quarters · filed 2026-04-15 | $7.47M derived: sum of 3 quarters · filed 2026-08-13 | $6.41M 10-K · filed 2026-04-15 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $7.47M derived: sum of 2 quarters · filed 2026-08-13 | $6.41M 10-Q · filed 2025-11-13 | -$2.31M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $7.47M 10-Q · filed 2026-08-13 | $6.41M 10-Q · filed 2026-08-13 | -$2.31M derived: sum of 3 quarters · filed 2026-08-13 | -$3.61M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$1.06M 10-Q · filed 2026-05-13 | -$9.78M derived: sum of 2 quarters · filed 2026-05-13 | -$11.08M derived: sum of 3 quarters · filed 2026-05-13 | -$12.13M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$8.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$10.02M derived: sum of 2 quarters · filed 2026-04-15 | -$11.07M derived: sum of 3 quarters · filed 2026-04-15 | -$13.61M 10-K · filed 2026-04-15 |
| 2024-09-30 | -$1.30M 10-Q · filed 2025-11-13 | -$2.35M derived: sum of 2 quarters · filed 2025-11-13 | -$4.89M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$1.05M 10-Q · filed 2025-08-14 | -$3.59M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | -$2.55M 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |